Thomas W. Flaig - Publications, H-index & Citations

Thomas W. Flaig

university of colorado anschutz medical campus

53H指数

393论文数

2.3W被引数

收录论文 74

发表时间

A Phase II Trial Using Grape Seed Extract for Prostate Cancer Patients With Nonmetastatic Prostate-Specific Antigen Progression After Local Therapy 使用葡萄籽提取物治疗局部治疗后非转移性前列腺特异性抗原进展的前列腺癌患者的II期临床试验

Molecular Carcinogenesis

IF3.2

2026-09-29

PREAI

Paul Maroni; Tad A. Manalo; Hannah Baker; Elizabeth R. Kessler; Andrew Nicklawsky; Victor Trevisanut; Thomas W. Flaig; Elaine T. Lam; James C. Moore; Dexiang Gao; Komal Raina; Rajesh Agarwal

Integrating clinically actionable biomarkers into bladder cancer care — recommendations from the International Bladder Cancer Group 将临床可操作生物标志物整合到膀胱癌护理中——国际膀胱癌小组的建议

Nature Reviews Urology

IF14.6

2026-08-05

PREAI

Patrick J. Hensley; Jeremy Y. C. Teoh; Roger Li; Shilpa Gupta; Laura Bukavina; Kent W. Mouw; Niyati Lobo; Brigida Anna Maiorano; Wei Shen Tan; Piyush Agarwal; Hikmat A. Al-Ahmadie; Trinity J. Bivalacqua; Liang Cheng; Thomas W. Flaig; Charles C. Guo; Amir Horowitz; Wassim Kassouf; Max R. Kates; Badrinath R. Konety; Janet B. Kukreja; Yair Lotan; David J. McConkey; Laura S. Mertens; Maria Carmen Mir; Marco Moschini; Andrea Necchi; Karima Oualla; Vignesh T. Packiam; Bogdana Schmidt; Roger J. Buckley; Ashish M. Kamat

EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma EV-103剂量递增/队列A：恩沃利单抗 vedotin 联合帕博利珠单抗治疗既往未治疗的局部晚期/转移性尿路上皮癌的5年随访

ESMO Open

IF8.3

2026-05-19

OAAI

J.E. Rosenberg; P.H. O'Donnell; D.P. Petrylak; T.W. Flaig; C.J. Hoimes; S. Gupta; N. Mar; T.W. Friedlander; S.T. Tagawa; M.A. Bilen; J.R. Brown; R.R. McKay; J.R. Merchan; S. Srinivas; S. Gorla; B.H. Moreno; G. Davis; H.S. Wirtz; Y. Zhu; M.I. Milowsky

Integrating New and Emerging Treatments Into Bladder Cancer Care 将新疗法和新兴疗法整合到膀胱癌护理中

Journal of the National Comprehensive Cancer Network

IF16.4

2026-05-01

PREAI

Flaig, Thomas W.; Peyton, Charles C.

Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium Enfortumab Vedotin在尿路上皮癌中的机制性见解与未来方向：第10届Leo & Anne Albert膀胱癌护理与研究学会年会的亮点

current oncology reports

IF3.4

2025-05-14

OAAI

Fahey, Catherine C.; Clark-Garvey, Sean; Porten, Sima; Kamat, Ashish M.; Flaig, Thomas W.; Taylor, John A.; Kim, William Y.; Milowsky, Matthew I.

Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group Gupta, S.; Hensley, P.J.; Li, R.; Choudhury, A.; Daneshmand, S.; Faltas, B.M.; Flaig, T.W.; Grass, G.D.; Grivas, P.; Hansel, D.E. 肌层浸润性膀胱癌的保膀胱策略：国际膀胱癌小组的建议。Eur. Urol. 2025, 已接受待发表。 [Google Scholar] [CrossRef]

European Urology

IF25.2

2025-04-22

PREAI

Shilpa Gupta; Patrick J. Hensley; Roger Li; Ananya Choudhury; Siamak Daneshmand; Bishoy M. Faltas; Thomas W. Flaig; G. Daniel Grass; Petros Grivas; Donna E. Hansel; Comron Hassanzadeh; Wassim Kassouf; Janet Kukreja; Arturo Mendoza-Valdés; Marco Moschini; Kent W. Mouw; Neema Navai; Andrea Necchi; Jonathan E. Rosenberg; Jeffrey S. Ross

Pharmacogenomics of chemotherapy induced peripheral neuropathy using an electronic health record-derived definition: a genome-wide association study 化疗诱导的外周神经病变的药物基因组学研究：基于电子健康记录衍生的定义的基因组-wide关联研究

SUPPORTIVE CARE IN CANCER

IF3

2025-04-08

PREAI

Jones, Michael K.; Nicklawsky, Andrew; Shortt, Jonathan; Pattee, Jack; Kennerley, Victoria; Eule, Corbin J.; Candelario, Nellowe; O'Donnell, Peter H.; Flaig, Thomas W.

Cardiovascular Safety in Oncology Clinical Trials JACC: CardioOncology Primer 肿瘤学临床试验中的心血管安全性 JACC: CardioOncology Primer

JACC: CARDIOONCOLOGY

IF12.8

2025-02-01

OAAI

Bonaca, Marc P.; Lang, Ninian N.; Chen, Alice; Amiri-Kordestani, Laleh; Lipka, Leslie; Zwiewka, Michal; Strnadova, Colette; Klaar, Sigrid; Dent, Susan; Janicijevic, Tijana Krnjeta; Herrmann, Joerg; Barac, Ana; Boer, Rudolf A. de; Deswal, Anita; Schou, Morten; Neilan, Tomas G.; van der Meer, Peter; Moslehi, Javid; Kondapalli, Lavanya; Ky, Bonnie; Fernandez, Teresa Lopez; Cornell, R. Frank; Flaig, Thomas W.; Hsia, Judith; Sharon, Elad; de Azambuja, Evandro; Seltzer, Jonathan; Januzzi, James L.; Petrie, Mark C.

Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database

PROSTATE CANCER AND PROSTATIC DISEASES

IF5.8

2024-11-21

PREAI

Eule, Corbin J.; Warren, Adam; Kuna, Elizabeth Molina; Robin, Tyler P.; Gershman, Boris; Kim, Simon P.; Flaig, Thomas W.

Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial

EUROPEAN UROLOGY

IF25.2

2024-10-01

PREAI

Plimack, Elizabeth R.; Tangen, Catherine; Plets, Melissa; Kokate, Rutika; Xiu, Joanne; Nabhan, Chadi; Ross, Eric A.; Grundy, Erin; Choi, Woonyoung; Dinney, Colin P. N.; Lee, I. -Ling C.; Fong, Megan; Lucia, M. Scott; Daneshmand, Siamak; Theodorescu, Dan; Goldkorn, Amir; Lerner, Seth P.; Flaig, Thomas W.; McConkey, David J.

Novel biomarker, ephrinB2 (B2), predicts resistance to treatment and poor overall survival (OS) metastatic urothelial carcinoma (mUC)新型生物标志物 ephrinB2 (B2) 可预测转移性尿路上皮癌 (mUC) 对治疗的抵抗性以及不良的总生存期 (OS)。

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Sadeghi, S.; Mar, N.; Tsao-Wei, D.; Siddiqi, I.; Freeman, D.; Torkko, K.; van Bokhoven, A.; Flaig, T.; Gill, P.; Kalebasty, A. Rezazadeh; Sonpavde, G. P.; Bellmunt, J.

Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) plus pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)研究EV-103剂量递增/队列A（DE/A）：在不可接受顺铂治疗的局部晚期或转移性尿路上皮癌（la/mUC）中，恩沃利单抗偶联物（EV）联合帕博利珠单抗（P）的一线（1L）5年随访研究

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Rosenberg, J. E.; Petrylak, D. P.; Flaig, T.; Hoimes, C. J.; Gupta, S.; O'Donnell, P. H.; Mar, N.; Friedlander, T.; Tagawa, S. T.; Bilen, M. A.; Brown, J. R.; McKay, R. R.; Merchan, J. R.; Srinivas, S.; Shetty, A.; Homet Moreno, B.; Davis, G.; Wirtz, H.; Zhu, Y.; Milowsky, M. I.

Updates in the Treatment of Metastatic Urothelial Cancer

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

IF16.4

2024-05-01

OAAI

Flaig, Thomas W.

Bladder Cancer, Version 3.2024 Featured Updates to the NCCN Guidelines

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

IF16.4

2024-05-01

OAAI

Flaig, Thomas W.; Spiess, Philippe E.; Abern, Michael; Agarwal, Neeraj; Bangs, Rick; Buyyounouski, Mark K.; Chan, Kevin; Chang, Sam S.; Chang, Paul; Friedlander, Terence; Greenberg, Richard E.; Guru, Khurshid A.; Herr, Harry W.; Hoffman-Censits, Jean; Kaimakliotis, Hristos; Kishan, Amar U.; Kundu, Shilajit; Lele, Subodh M.; Mamtani, Ronac; Mian, Omar Y.; Michalski, Jeff; Montgomery, Jeffrey S.; Parikh, Mamta; Patterson, Anthony; Peyton, Charles; Plimack, Elizabeth R.; Preston, Mark A.; Richards, Kyle; Sexton, Wade J.; Siefker-Radtke, Arlene O.; Stewart, Tyler; Sundi, Debasish; Tollefson, Matthew; Tward, Jonathan; Wright, Jonathan L.; Cassara, Carly J.; Gurski, Lisa A.

A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab 探索未经治疗的局部晚期或转移性尿路上皮癌的新治疗组合: enfortumab vedotin加pembrolizumab

FUTURE ONCOLOGY

IF2.6

2023-11-23

OAAI

Hoimes, Christopher J.; Flaig, Thomas W.; Milowsky, Matthew, I; Friedlander, Terence W.; Bilen, Mehmet Asim; Gupta, Shilpa; Srinivas, Sandy; Merchan, Jaime R.; Mckay, Rana R.; Petrylak, Daniel P.; Sasse, Carolyn; Moreno, Blanca Homet; Yu, Yao; Carret, Anne-Sophie; Rosenberg, Jonathan E.

Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314

EUROPEAN UROLOGY ONCOLOGY

IF9.3

2023-10-01

PREAI

Lu, Yi-Tsung; Plets, Melissa; Morrison, Gareth; Cunha, Alexander T.; Cen, Steven Y.; Rhie, Suhn K.; Siegmund, Kimberly D.; Daneshmand, Siamak; Quinn, David I.; Meeks, Joshua J.; Lerner, Seth P.; Petrylak, Daniel P.; Mcconkey, David; Flaig, Thomas W.; Thompson Jr, Ian M.; Goldkorn, Amir

Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Sridhar, S.; O'Donnell, P. H.; Flaig, T. W.; Rosenberg, J. E.; Hoimes, C. J.; Milowsky, M. I.; Srinivas, S.; George, S.; McKay, R. R.; Petrylak, D. P.; Barata, P. M. Coelho; Hwang, C.; Cruz-Correa, M.; Iafolla, M.; Mckean, M.; Dreicer, R.; Brancato, S.; Lukas, J. J.; Yu, Y.; Moon, H.

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314 NCT02177695) ;

EUROPEAN UROLOGY

IF25.2

2023-09-01

OAAI

Flaig, Thomas W.; Tangen, Catherine M.; Daneshmand, Siamak; Alva, Ajjai Shivaram; Lucia, M. Scott; McConkey, David James; Theodorescu, Dan; Goldkorn, Amir; Milowsky, Matthew I.; Bangs, Rick; MacVicar, Gary R.; Bastos, Bruno R.; Fowles, Jared S.; Gustafson, Daniel L.; Plets, Melissa; Thompson Jr, Ian M.; Lerner, Seth P.

Burden of Cardiovascular Disease in Immune Checkpoint Inhibitor-Treated Patients Reconciling Adjudicated and Coded Outcomes

JACC: CARDIOONCOLOGY

IF12.8

2022-12-01

OAAI

Kondapalli, Lavanya; Hsia, Judith; Miller, Ronni; Flaig, Thomas W.; Bonaca, Marc P.

Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations

PROSTATE CANCER AND PROSTATIC DISEASES

IF5.8

2022-11-19

PREAI

Eule, Corbin J.; Flaig, Thomas W.; Wong, Katy; Graf, Ryon; Lam, Elaine T.

研究方向